This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Mucopolysaccharidosis (MPS)	Arylsulfatase G (ARSG)	<p>Mouse and <i>in vitro</i> studies suggest restoring ARSG levels could be useful for treating MPS type IIIE, a lysosomal storage disorder caused by impaired processing of heparan sulfate. Mice lacking Arsg accumulated unprocessed heparan sulfate degradation products and developed neurological abnormalities resembling MPS type IIIE. <i>In vitro</i>, recombinant ARSG degraded heparan sulfate, whereas a nonselective control enzyme did not. Next steps could include formulating a recombinant version of ARSG for preclinical testing.</p> <p>SciBX 5(29); doi:10.1038/scibx.2012.758 Published online July 26, 2012</p>	Patent and licensing status undisclosed	<p>Kowalewski, B. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online June 11, 2012; doi:10.1073/pnas.1202071109 Contact: Thomas Dierks, Bielefeld University, Bielefeld, Germany e-mail: thomas.dierks@uni-bielefeld.de</p>